These MVA-based vaccine candidates were combined in a DNA prime/MVA boost approach with DNA-based vectors (DNA-Tau4R2N or DNA-Tau3RC) to define if any tau-specific immune response could be obtained and to evaluate whether a control in the disease progression could be observed in a mouse model of tauopathies, as a step toward developing more effective vaccine candidates. This evidence concerns the gene MAPT and tauopathy.